Sara Payamifar , Amin Foroozandeh , Mehrab Pourmadadi , Majid Abdouss , Mohammad Hasanzadeh
{"title":"Cyclodextrin-based nanocarriers as promising scaffolds for overcoming challenges of doxorubicin delivery in cancer chemotherapy","authors":"Sara Payamifar , Amin Foroozandeh , Mehrab Pourmadadi , Majid Abdouss , Mohammad Hasanzadeh","doi":"10.1016/j.carpta.2025.100677","DOIUrl":null,"url":null,"abstract":"<div><div>Pharmacotherapy, a cornerstone in cancer treatment, faces significant challenges due to the inherent water-insolubility of many potent anticancer drugs. Cyclodextrins (CDs) have emerged as a promising solution in the field of drug delivery. This review highlights the use of CD-based nanocarrier systems as a transformative approach for encapsulating and precisely delivering doxorubicin (DOX) in cancer therapy. By exploring the synergistic potential of these nanocarriers, this study emphasizes their capability to overcome longstanding challenges and advance the frontiers of cancer treatment. Additionally, this review surveyed the application of CDs-incorporated nanoparticles for the targeted delivery of DOX. Then, several challenges associated with the effective pharmacotherapy of cancer using CDs-DOX, including issues related to drug loading and maintaining consistent release profiles that achieve high and sustained drug loading levels over time. In conclusion, by incorporating CDs into their formulations, it is anticipate the development of advanced chemotherapy agents that effectively address the challenges of efficient cancer treatment. Looking ahead, the ongoing advancement of nanocarrier systems comprising CD-based molecules holds great promise for improving the quality of life for patients worldwide. This study outlines how CDs address issues such as inconsistent drug loading and sustained release, aiming to achieve high and prolonged drug levels. The point that incorporating CDs could lead to the development of advanced chemotherapy agents that improve patient quality of life highlights a forward-looking and innovative aspect. By exploring CD-incorporated nanoparticles for the targeted delivery of DOX, the study aligns with cutting-edge research trends in precision medicine. The focus on CDs as nanocarrier scaffolds to address longstanding challenges in drug delivery is a key novel aspect. This overview collectively underscores the novel contributions of the study in advancing cancer chemotherapy through innovative nanotechnology.</div></div>","PeriodicalId":100213,"journal":{"name":"Carbohydrate Polymer Technologies and Applications","volume":"9 ","pages":"Article 100677"},"PeriodicalIF":6.2000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carbohydrate Polymer Technologies and Applications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666893925000179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0
Abstract
Pharmacotherapy, a cornerstone in cancer treatment, faces significant challenges due to the inherent water-insolubility of many potent anticancer drugs. Cyclodextrins (CDs) have emerged as a promising solution in the field of drug delivery. This review highlights the use of CD-based nanocarrier systems as a transformative approach for encapsulating and precisely delivering doxorubicin (DOX) in cancer therapy. By exploring the synergistic potential of these nanocarriers, this study emphasizes their capability to overcome longstanding challenges and advance the frontiers of cancer treatment. Additionally, this review surveyed the application of CDs-incorporated nanoparticles for the targeted delivery of DOX. Then, several challenges associated with the effective pharmacotherapy of cancer using CDs-DOX, including issues related to drug loading and maintaining consistent release profiles that achieve high and sustained drug loading levels over time. In conclusion, by incorporating CDs into their formulations, it is anticipate the development of advanced chemotherapy agents that effectively address the challenges of efficient cancer treatment. Looking ahead, the ongoing advancement of nanocarrier systems comprising CD-based molecules holds great promise for improving the quality of life for patients worldwide. This study outlines how CDs address issues such as inconsistent drug loading and sustained release, aiming to achieve high and prolonged drug levels. The point that incorporating CDs could lead to the development of advanced chemotherapy agents that improve patient quality of life highlights a forward-looking and innovative aspect. By exploring CD-incorporated nanoparticles for the targeted delivery of DOX, the study aligns with cutting-edge research trends in precision medicine. The focus on CDs as nanocarrier scaffolds to address longstanding challenges in drug delivery is a key novel aspect. This overview collectively underscores the novel contributions of the study in advancing cancer chemotherapy through innovative nanotechnology.